Niraparib: all 158 studies that test it

Page 1 of 2. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.

• A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06887933Phase 4
• Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingNCT06747845Phase 2
• A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingNCT06594679Phase 1/2
• Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingNCT06412120Phase 4
• Niraparib and Temozolomide in Patients GlioblastomaNot yet recruitingNCT06258018Phase 1/2
• Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination DeficiencyNot yet recruitingNCT06237205Phase 2
• Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingNCT06180356Phase 2
• Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingNCT06141265Phase 2
• SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingNCT05990192Phase 2
• Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingNCT05961124Phase 2
• Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingNCT05718323Phase 2
• Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingNCT05700721Phase 2
• Combination Therapy in Cancers With Mutations in DNA Repair GenesRecruitingNCT05694715Phase 1
• A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian CancerNot yet recruitingNCT05641506Phase 2
• Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
• Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
• Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingNCT05526989Phase 2
• A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCErNot yet recruitingNCT05519670Phase 1/2
• Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingNCT05461690Phase 2
• PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNot yet recruitingNCT05232006Phase 2
• PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingNCT05187208Phase 4
• Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingNCT04947254Phase 2
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
• Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingNCT04716686Phase 2
• Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingNCT04681469Phase 2
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
• Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingNCT03651206Phase 2/3
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)TerminatedNCT06964165Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
• PARP Inhibition for Gliomas (PI-4G or π4g)TerminatedNCT05297864Phase 2Results posted
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsTerminatedNCT05169437Phase 2Results posted
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseActive, not recruitingNCT04915755Phase 3Results posted
• Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results posted
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedNCT04544995Phase 1Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)Active, not recruitingNCT04497844Phase 3Results posted
• Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedNCT04493060Phase 2Results posted
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT04475939Phase 3Results posted
• Niraparib + Dostarlimab + RT in Pancreatic CancerCompletedNCT04409002Phase 2Results posted
• Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedNCT04313504Phase 2Results posted
• Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringCompletedNCT04037254Phase 1/2Results posted
• Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsTerminatedNCT04030559Phase 2Results posted
• Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03983993Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric AdenocarcinomaTerminatedNCT03840967Phase 2Results posted
• Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerCompletedNCT03759600Phase 2Results posted
• Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerCompletedNCT03759587Phase 2Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingNCT03748641Phase 3Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the CervixTerminatedNCT03644342Phase 1/2Results posted
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results posted
• A Study of Niraparib as Single Agent in Participants With Advanced Solid TumorsCompletedNCT03497429Phase 1Results posted
• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results posted
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results posted
• Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerCompletedNCT03329937Phase 1Results posted
• Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleCompletedNCT03329001Phase 1Results posted
• A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyCompletedNCT03326193Phase 2Results posted
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)CompletedNCT03207347Phase 2Results posted
• Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastCompletedNCT03154281Phase 1Results posted
• An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesCompletedNCT02854436Phase 2Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3Results posted
• Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)TerminatedNCT02500901Phase 1Results posted
• A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results posted
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results posted
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results posted
• Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate CancerWithdrawnNCT06527690Phase 2
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaActive, not recruitingNCT06388733Phase 3
• Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal CancersWithdrawnNCT06365970Phase 2
• ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsWithdrawnNCT06161493Phase 1
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsActive, not recruitingNCT06077877Phase 1/2
• Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2
• Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian CancerWithdrawnNCT05672095Phase 1/2
• Reirradiation and Niraparib in Patients With Recurrent GlioblastomaWithdrawnNCT05666349Phase 1
• A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNAActive, not recruitingNCT05515575Phase 2
• Niraparib Efficacy in Patient With Unresectable MesotheliomaCompletedNCT05455424Phase 2
• Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic CancerTerminatedNCT05442749Phase 2
• Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyWithdrawnNCT05412706Phase 2
• Niraparib In Recurrent IDH 1/2 GliomasActive, not recruitingNCT05406700Early Phase 1
• A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPiStatus unknownNCT05385068Phase 2
• A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• Niraparib in High-grade Endometrial Cancer TrialWithdrawnNCT05289648Early Phase 1
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2
• Niraparib for the Treatment of LeiomyosarcomaWithdrawnNCT05174455Phase 2
• The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerStatus unknownNCT05162196Phase 2
• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
• Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2
• Niraparib in Tumors Metastatic to the CNSActive, not recruitingNCT04992013Phase 2
• UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2
• A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedNCT04926324Phase 1
• Maintenance Niraparib and Dostarlimab in Advanced CholangiocarcinomaWithdrawnNCT04895046Phase 2

← Niraparib overview